In fact, clinical investigators have grappled with the problem of defining the boundaries of normal cognitive aging for over 40 years. In 1962, Kral3 coined the term “benign senescent forget-fulness” (BSF) to describe a population of nursing-home residents with mild memory deficits that were anticipated to remain stable over time. Subsequently, this www.selleckchem.com/products/AZD8931.html concept has undergone

many refinements resulting in a proliferation Inhibitors,research,lifescience,medical of proposed entities including age-associated memory impairment (AAMI),4 age-consistent memory impairment (ACMI),5 late-life forgetfulness (LLP),5 and ARCD.1 These constructs were intended to identify subjects whose cognitive performance had deteriorated below values established for young adults, but were Inhibitors,research,lifescience,medical not expected to undergo significant further decline and were not believed to harbor neuropathological changes. Nevertheless, a paucity of carefully collected follow-up data makes it impossible to validate this hypothesis and it remains unclear whether meeting

diagnostic criteria for any of these syndromes really implies cognitive stability in contrast to these proposed definitions Inhibitors,research,lifescience,medical of “normal” brain aging, Levy’s “aging-associated cognitive decline” (AACD)6 included subjects who performed below normative levels for their own age-group making a pathological basis more likely. In the 1980s, global clinical staging scales for the study of AD were developed to more rigorously classify the broad spectrum of intellectual performance found in geriatric populations. Two of the most commonly used scales, the Global Deterioration Scale (GDS)7 and the Clinical Dementia Rating (CDR),8 both recognized the need to categorize subjects without dementia who nevertheless exhibited some evidence Inhibitors,research,lifescience,medical for cognitive dysfunction. Subjects classified as GDS stage 3 or CDR stage 0.5 were considered cases of “questionable,”

“borderline ” or “preclinical” AD, whose cognitive status Inhibitors,research,lifescience,medical was intermediary between normal/AAMI/ARCD levels and mild dementia. Other global dementia scales have defined similar transitional stages, for example, “minimal dementia” from the Cambridge Mental Disorders of the Elderly Examination (CAMDEX)9 and “limited cognitive disturbance” from the Comprehensive Assessment Dichloromethane dehalogenase and Referral Evaluation (CARE).10 Other constructs, such as isolated memory loss,11 mild cognitive disorder,12 mild neurocognitive disorder,1 and cognitive impairment-no dementia (CIND),13-45 were intended to capture similar levels of overall intellectual performance. It was in this historical context that the expression “mild cognitive impairment” gradually entered the lexicon of the aging and dementia literature. In 1988, Reisberg et al16 used it as a descriptive term coinciding with the GDS stage 3. Three years later, the term appeared in the title of an article by Flicker et al describing GDS stage 3 subjects at risk for dementia.